Polylog
Sign inSubscribe
← The Global Intelligence Brief

Morning Edition · Thursday, July 23, 2026Published at 1:16 AM EDT · New York

India's Q1 Earnings Split as Lenders Beat, Drugmakers Miss, and Investors Stay Selective

IndusInd Bank posted a 72 percent profit jump yet fell 5 percent, Dr Reddy's dropped 9 percent on a weak quarter, and Oracle Financial Services rose after a 121 percent income surge.

Save
India's Q1 Earnings Split as Lenders Beat, Drugmakers Miss, and Investors Stay Selective

India's June-quarter earnings drew sharp, divergent reactions. IndusInd Bank reported net profit up 72 percent from a year earlier to 1,037 crore rupees, yet its shares fell about 5 percent as net interest income stayed roughly flat, a sign investors are scrutinizing the quality of growth rather than the headline number.

Pharmaceuticals disappointed. Dr Reddy's Laboratories dropped 9 percent after net profit fell 69 percent to 443 crore rupees, affected by a charge tied to a key drug ingredient, prompting several brokerages to cut price targets.

Financial-technology and consumer names fared better. Oracle Financial Services Software rose 5 percent after net income jumped 121 percent, and food-delivery and quick-commerce operator Eternal gained 3 percent as brokerages reaffirmed positive views on its Blinkit unit.

Part of a tracked trend

India's Domestic Market Absorbs Shocks

India's domestic-demand-led equity market and financial-sector earnings repeatedly cushion it from external oil and rate shocks, drawing flows seeking growth insulated from global stress.

What this means

The split shows a domestic market rewarding durable, domestically driven earnings, in financials and consumer platforms, while punishing companies exposed to external pricing pressure, as in generic pharmaceuticals. That selectivity is what lets India's equity market draw flows even during an external oil and rate shock: the earnings base is anchored in domestic demand rather than exports. The exposed parties are export-facing sectors such as drugmakers, while lenders and consumer-platform companies benefit from the internal growth channel.

What to watch

  • Bank net-interest-margin trends across the sector, which determine whether profit growth is sustainable or flattering.
  • Further brokerage target cuts in pharma, a read on how deep the ingredient-cost pressure runs.
  • Quick-commerce profitability at Eternal and peers, the test of whether the consumer-platform growth is real.

Observations to monitor, not financial advice.

4 sources

Synthesized from: The Economic Times (IndusInd) · The Economic Times (Dr Reddy's) · The Economic Times (Oracle Financial) · The Economic Times (Eternal)

More from this edition